Ibrutinib (PCI-32765)

For research use only. Not for use in humans.

目录号:S2680 中文名称:依鲁替尼

Ibrutinib (PCI-32765) Chemical Structure

CAS No. 936563-96-1

Ibrutinib (PCI-32765)是一种有效的,高选择性的Brutons tyrosine kinase (Btk)抑制剂,无细胞试验中IC50为0.5 nM,对Bmx, CSK, FGR, BRK及HCK适度有效,对EGFR, Yes, ErbB2, JAK3等作用效果较弱。Ibrutinib 可作为Btk配体用于合成包括P13I在内的一系列PROTAC

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2226.41 现货
RMB 1392.54 现货
RMB 7922.62 现货
RMB 20229.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Ibrutinib (PCI-32765)发表文献421篇:

产品安全说明书

Target Protein Ligand抑制剂选择性比较

生物活性

产品描述 Ibrutinib (PCI-32765)是一种有效的,高选择性的Brutons tyrosine kinase (Btk)抑制剂,无细胞试验中IC50为0.5 nM,对Bmx, CSK, FGR, BRK及HCK适度有效,对EGFR, Yes, ErbB2, JAK3等作用效果较弱。Ibrutinib 可作为Btk配体用于合成包括P13I在内的一系列PROTAC
靶点
BTK [1]
(Cell-free assay)
BLK [1]
(Cell-free assay)
Bmx [1]
(Cell-free assay)
CSK [1]
(Cell-free assay)
FGR [1]
(Cell-free assay)
0.5 nM 0.5 nM 0.8 nM 2.3 nM 2.3 nM
体外研究

Ibrutinib有效可逆且选择性抑制Btk酶活性。Ibrutinib作用于 BCR 通路激活的 DOHH2细胞系, 抑制Btk自磷酸化, Btk's 生理底物 PLCγ磷酸化, 和更远一点的下游激酶ERK的磷酸化,IC50分别为11 nM, 29 nM 和 13 nM。[1] Ibrutinib作用于慢性淋巴细胞白血病 (CLL) 细胞,诱导细胞毒性,这种作用存在剂量和时间依赖性。此外, Ibrutinib诱导 caspase依赖性细胞死亡通路激活,且在TLR信号后,抑制CLL细胞增殖能力。[2] 最新研究显示Ibrutinib抑制 BCR激活的原代 B细胞增殖,IC50 为8 nM,且抑制 原代单核细胞中TNFα, IL-1β 和 IL-6产量, IC50 分别为2.6 nM, 0.5 nM, 和 3.9 nM。 [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human Rec1 cells MnHESpVv[3Srb36gZZN{[Xl? M1fiNlIvPSEQvF2= NVrucHpRPiCq M3TkfWlvcGmkaYTpc44hd2ZiTInuJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDS[YMyKGOnbHzzJIF1KDJwNTD1UUBqdmO3YnH0[YQh\m:{IE[gbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdibXX0bI9l MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ{Mki3O{c,OjV{MkK4O|c9N2F-
human WSU-NHL cells MlK2R5l1d3SxeHnjxsBie3OjeR?= MYS3NkBp MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDXV3UuVkiOIHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIx2dWmwZYPj[Y51KGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwMEmg{txO MkDkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
human SU-DHL6 cells MY\DfZRwfG:6aXRCpIF{e2G7 NVzWflFUPzJiaB?= NITIXGlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUXS2GSFy2JINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGy3bXnu[ZNk\W62IHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVgh|ryPLh?= MlHXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
human DOHH2 cells NUfUO4p5S3m2b4TvfIlkyqCjc4PhfS=> Mne3O|IhcA>? NET3PHdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFV0iKMjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkSxJO69VS5? NEnBNo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
Sf9 cells MUPGeY5kfGmxbjDhd5NigQ>? NVH1XpUxOSCq MlKxTY5pcWKrdHnvckBw\iCOWV6tRUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|IHHmeIVzKDZyIH3pcpMh[nliVGKtSnJGXCCDc4PhfUwhUUN3ME2wMlIh|ryPLh?= NFHwUJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm1PFU1Pyd-MkG5OVg2PDd:L3G+
human Ramos cells MmjoSpVv[3Srb36gZZN{[Xl? MXuxJIg> NYrjWVdoUW6qaXLpeIlwdiCxZjDCeIshcW5iaIXtZY4hWmGvb4OgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCSTFOt[4FudWF{IIDoc5NxcG:{eXzheIlwdiCjdDDUfZIyOjF5IHHmeIVzKDFiaIKgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m|LDDJR|UxRTF2IH7NMi=> MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
human Pfeiffer cells NULsdIp[TnWwY4Tpc44h[XO|YYm= NVPPPXRjPzJiaB?= MoT3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVIZmcW[oZYKgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MjDuUU4> NYDF[ohtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
Sf9 cells NWT5b|hZTnWwY4Tpc44h[XO|YYm= M2D2blEhcA>? NVXxTGtjUW6qaXLpeIlwdiCxZjDoeY1idiCodXzsMYxmdme2aDDCWGsh\XiycnXzd4VlKGmwIGPmPUBk\WyuczD1d4lv\yCIQV2tV5JkfGmmZTDw[ZB1cWSnIHHzJJN2[nO2cnH0[UBi\nSncjC2NEBucW6|IHL5JHRTNU[URWSgRZN{[XoxvJygTWM2OD1yLkWgcm0v NHvsZoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm1PFU1Pyd-MkG5OVg2PDd:L3G+
Sf9 insect cells MUTGeY5kfGmxbjDhd5NigQ>? NXzrXm5oPjBibXnudy=> NYXOcXIzUUN3MDC9JFAvODByMzFOwG0> NHXPUVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG0OlE{Pid-MkmxOFYyOzZ:L3G+
sf9 cells MmXiSpVv[3Srb36gZZN{[Xl? M{nUe2lEPTBiPTCwMlAxODNizszN MoTNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N|YoRjJ5OUm0O|M3RC:jPh?=
Sf9 insect cells NIjGXoJHfW6ldHnvckBie3OjeR?= MXu2NEBucW6| M4G1cGlEPTBiPTCwMlAxODN2IN88US=> MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzlzMkG3OUc,Ojd7MUKxO|U9N2F-
Sf9 insect cells M3P1emZ2dmO2aX;uJIF{e2G7 NHXCfWM3OCCvaX7z M2LsWGlEPTBiPTCwMlAxODN2IN88US=> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR|Mkm0Okc,Ojh2M{K5OFY9N2F-
Sf9 insect cells MmDvSpVv[3Srb36gZZN{[Xl? NIDPbGQ3OCCvaX7z NI\TZYxKSzVyIE2gNE4xODB|NDFOwG0> M2DUOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUW2NFM4Lz5{N{m1OlA{PzxxYU6=
Sf9 cells MXjGeY5kfGmxbjDhd5NigQ>? MlX2OlAhdWmwcx?= NGDJNZNKSzVyIE2gNE4xODB2IN88US=> NVHYTWd3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR|PD;hQi=>
Sf9 cells NHLhe4pHfW6ldHnvckBie3OjeR?= NEmwd4Q3OCCvaX7z NHPibpRKSzVyIE2gNE4xODB3IN88US=> NH\0[|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm1PFU1Pyd-MkG5OVg2PDd:L3G+
Ramos cells NX\GcmF5TnWwY4Tpc44h[XO|YYm= NXWxT|NyOSCq NV;6NHZ1UUN3MDC9JFAvODByNTFOwG0> MkPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OECyOlEoRjJ6MkiwNlYyRC:jPh?=
Sf9 cells NIjDZo5HfW6ldHnvckBie3OjeR?= MV[2NEBucW6| M3nKWGlEPTBiPTCwMlAxOSEQvF2= MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5N{[wPEc,OzByN{e2NFg9N2F-
Pfeiffer cells NE\WflJEgXSxdH;4bYNqfHliYYPzZZk> M1m3e|czKGh? NUXGZVB[T0l3MDC9JFAvODB{IN88US=> Ml7CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
B cells MoPSSpVv[3Srb36gZZN{[Xl? MUKxJIg> NV;0OpVIUUN3MDC9JFAvODB2NjFOwG0> M2XqVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkmwPVg5Lz5|MEK5NFk5QDxxYU6=
Sf9 insect cells NYG1ZmhZTnWwY4Tpc44h[XO|YYm= M3fFUVIhfG9iNkCgcYlvew>? MlW2T4khRSByLkCwOFgh|ryP NYLQepF{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
Ramos cells MUDGeY5kfGmxbjDhd5NigQ>? MnnSNUBp M3rzfGlEPTBiPTCwMlAxPzVizszN M{nWNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
Sf9 insect cells NGHaWoRHfW6ldHnvckBie3OjeR?= MYq2NEBucW6| NF;Iem1KSzVyIE2gNE4xODhizszN MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
TMD8 cells NHSyd5pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NYrSc5R[PzJiaB?= MnvMTWM2OCB;IECuNFEh|ryP M3vhbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{G1NFI{Lz5{OUexOVAzOzxxYU6=
CD19+ B cells MVnGeY5kfGmxbjDhd5NigQ>? NXvuboI1OSCq NHSxW|lKSzVyIE2gNE4xOTJizszN NI[4O4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1O|k5Oid-Mkm0OVc6QDJ:L3G+
Sf9 insect cells M1WwfWZ2dmO2aX;uJIF{e2G7 MYW2NEBucW6| NH:0fVNKSzVyIE2gNE4xOTJizszN MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
Ramos cells M3HWT2Z2dmO2aX;uJIF{e2G7 M3TCXlEhcA>? NGXIfGdKSzVyIE2gNE4xOTRizszN NHr5blk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
Sf9 insect cells NEDadmNHfW6ldHnvckBie3OjeR?= MlrNNUBp MlfJTWM2OCB;IECuNFE1PCEQvF2= MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTdzNUCyN{c,Ojl5MUWwNlM9N2F-
Sf9 insect cells NYTRZmhjTnWwY4Tpc44h[XO|YYm= NFXwUoU3OCCvaX7z MXTJR|UxKD1iMD6wNVYyKM7:TR?= MlHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzNE[xN|YoRjJ7MUS2NVM3RC:jPh?=
HCC827 cells NWLPZoxXSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NHPZVJE4OiCq NG\aXJlKSzVyIE2gNE4xOzlizszN M2C4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{O0OVgyLz5{OEezOFU5OTxxYU6=
PC9 cells NHLSfVJHfW6ldHnvckBie3OjeR?= NG\jUmU4OiCq NHXxcmRIUTVyIE2gNE4xPSEQvF2= MnnGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
Sf9 cells MoTDSpVv[3Srb36gZZN{[Xl? Mln1OlAhdWmwcx?= M1\yTGlEPTBiPTCwMlEh|ryP MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODByNkG0N{c,OzByME[xOFM9N2F-
H3255 cells NYjz[odETnWwY4Tpc44h[XO|YYm= Ml24O|IhcA>? MnT3S2k2OCB;IECuNVEh|ryP M2DPNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
BaF3 cells MX\GeY5kfGmxbjDhd5NigQ>? Mln0O|IhcA>? MkTGS2k2OCB;IECuNVIh|ryP MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ|MEW1N{c,OjZ4M{C1OVM9N2F-
BAF3 cells Mkn3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NYnWZXNXPzJiaB?= M{\EeGdKPTBiPTCwMlEzKM7:TR?= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
Sf9 insect cells NF;2SolHfW6ldHnvckBie3OjeR?= MWO2NEBucW6| NF\yfHVKSzVyIE2gNE4yOjNizszN M3z2NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
Sf9 insect cells MofXSpVv[3Srb36gZZN{[Xl? MYG2NEBucW6| NHz6NIVKSzVyIE2gNE4yPDZizszN M37FSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
BAF3 cells Mm\OSpVv[3Srb36gZZN{[Xl? NYP4Sm9QPzJiaB?= MVvHTVUxKD1iMD6xOkDPxE1? NI\zWpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
Sf9 cells MVnGeY5kfGmxbjDhd5NigQ>? MkX1OlAhdWmwcx?= MXfJR|UxKD1iMD6yJO69VQ>? NFm3eVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm1PFU1Pyd-MkG5OVg2PDd:L3G+
MV411 cells MnjrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFHmSJZIUTVyIE2gNE4zPSEQvF2= MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
MV4-11 cells NUDjS|g5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M2nJ[VczKGh? NF7qfGtIUTVyIE2gNE4{OyEQvF2= M3:5O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkOwOVU{Lz5{Nk[zNFU2OzxxYU6=
MV4-11 cells NXzJSIlVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M{Hq[VczKGh? MUjHTVUxKD1iMD6zN{DPxE1? M4fodFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
DOHH2 cells NYrDR3Q{S3m2b4TvfIlkcXS7IHHzd4F6 MVS3NkBp NXnlTWR3T0l3MDC9JFAvPDFizszN MlfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
HCC827 cells NXjud4s5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MUC5OkBp NU\K[pBSTUN3MDC9JFAvPDVizszN MlX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O|UoRjJ6OEWzOVc2RC:jPh?=
SU-DHL6 cells MWrDfZRwfG:6aXPpeJkh[XO|YYm= NUniZVAxPzJiaB?= M3GwcGdKPTBiPTCwMlU5KM7:TR?= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
M07e cells NVeyeZF{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVu4fXQxT0l3MDC9JFAvPTlizszN MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
NCI-H1975 cells M333WmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NVTsVWd4QTZiaB?= NGruWVVGSzVyIE2gNE43PCEQvF2= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O|U9N2F-
SU-DHL-2 cells NGjUblFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkPiS2k2OCB;IECuOlQh|ryP M2TxdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
HEK293T cells M3TKe2Z2dmO2aX;uJIF{e2G7 MmDaNUBp NHnBOHRKSzVyIE2gNE46KM7:TR?= M1PIcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiwNlYyLz5{OEK4NFI3OTxxYU6=
Ramos cells NE\EN4lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= Mn\OO|IhcA>? MWTJR|UxKD1iMD65NkDPxE1? MlvjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5MUWwNlMoRjJ7N{G1NFI{RC:jPh?=
BA/F3 cells M4jTNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M{nTOlczKGh? MYLJR|UxKD1iMTFOwG0> M3;3dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW4OVIyLz5{NkK1PFUzOTxxYU6=
WSU-NHL cells M1PZOWN6fG:2b4jpZ4l1gSCjc4PhfS=> M{DFSlczKGh? MVrHTVUxKD1iMT6wPUDPxE1? MnHnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
NCI-H1975 cells NWHpO|BNTnWwY4Tpc44h[XO|YYm= Mnr2O|IhcA>? MUjHTVUxKD1iMT6yJO69VQ>? M3\yOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H1975 cells NUTYcIpGSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MXm3NkBp MkHPTWM2OCB;IEGuNlch|ryP MnfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5M{S1PFEoRjJ6N{O0OVgyRC:jPh?=
Raji cells MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MoTvOFghcA>? MVPJR|UxKD1iMT60PUDPxE1? MmHoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NkeyPVUoRjJ7NU[3Nlk2RC:jPh?=
Pfeiffer cells MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoPhS2k2OCB;IEGuOkDPxE1? NITBOIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
A431 cells MkO3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NUTr[ZVWQTZiaB?= MoX6SWM2OCB;IEKuN|gh|ryP MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O|U9N2F-
BAF3 cells NF3jO5NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MXW3NkBp NVfIU5RNT0l3MDC9JFIvPSEQvF2= NHrCbJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
U937 cells MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnrFS2k2OCB;IEKuPUDPxE1? NUL5PFRCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
NB4 cells MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1uzS2dKPTBiPTCzJO69VQ>? M2\L[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
Ramos cells NUXybJZ{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{XZUmdKPTBiPTCzMlQh|ryP MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
SKM1 cells MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlrES2k2OCB;IEOuOkDPxE1? NXPrPFY3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
U2932 cells Mof4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVXHTVUxKD1iND60JO69VQ>? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
Ramos cells Ml;1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M4fQUFczKGh? Mn\yTWM2OCB;IEWuNVQh|ryP MmC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xOFMoRjNyMEC2NVQ{RC:jPh?=
Ramos cells NX33fXBOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MmnxOFghcA>? NY\sWlgzUUN3MDC9JFUvOTRizszN NH\UXGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m1OlA{Pyd-Mke5OVYxOzd:L3G+
Ramos cells Mm\pRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NUj6NnRPPDhiaB?= M2K2bmlEPTBiPTC1Mlg5KM7:TR?= NFnnNYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNlk1Pid-Mki0N|I6PDZ:L3G+
Ramos cells MUDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? Mn3YO|IhcA>? MUDJR|UxKD1iNj62NkDPxE1? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2NkGzOkc,OjlzNE[xN|Y9N2F-
K562 cells MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NYnJ[3BkPDhiaB?= NEP3bY9KSzVyIE2gO{42KM7:TR?= MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5N{[wPEc,OzByN{e2NFg9N2F-
HL60 cells NXzBT|NESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M17ESVQ5KGh? MXHJR|UxKD1iODFOwG0> M4C1V|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe3OlA5Lz5|MEC3O|YxQDxxYU6=
Ramos cells NVjBbIsxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= Mo\iOFghcA>? Mn62TWM2OCB;IEiuNVEh|ryP MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOkc,Ojd7OUS3N|Y9N2F-
Ramos cells MoK0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NILpTIQ1QCCq M4\Gb2lEPTBiPTC4MlI3KM7:TR?= NGDtN2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW2O|I6PSd-Mkm1OlczQTV:L3G+
OCI-AML3 cells NH7JT3ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHn0ZW5IUTVyIE2gPU4zKM7:TR?= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
BAF3 cells NWLDbJhVS3m2b4TvfIlkcXS7IHHzd4F6 MVO3NkBp NWrnO|Y{T0l3MDC9JFExKM7:TR?= MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ|MEW1N{c,OjZ4M{C1OVM9N2F-
BAF3 cells NIqyOJZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NF3kRWc4OiCq M1W3UmdKPTBiPTCxNEDPxE1? NYHoUlRERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ|PD;hQi=>
BAF3 cells MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYLVTW5NPzJiaB?= NXSzSZpqT0l3MDC9JFExKM7:TR?= M2LtWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NAMALWA cells NX3qcWV2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MYO3NkBp M2rmcmlEPTBiPTCxNE41PSEQvF2= M4TNc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUS2NVM3Lz5{OUG0OlE{PjxxYU6=
Ramos cells MmjkRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? Mkf2OFghcA>? Mmn6TWM2OCB;IEGyMlYh|ryP M1ridVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGyNVc2Lz5{N{mxNlE4PTxxYU6=
Raji cells M{HoN2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 Ml\SOFghcA>? NHTPNlZKSzVyIE2gNVQvOiEQvF2= M3;DNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe3OlA5Lz5|MEC3O|YxQDxxYU6=
Raji cells MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MomzOFghcA>? NELpNXZKSzVyIE2gNVUvOiEQvF2= NE\tUWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{Pid-Mke5PVQ4OzZ:L3G+
MIAPaCa2 cells NHjkN3ZEgXSxdH;4bYNqfHliYYPzZZk> NHTOcJY{KGSjeYO= MoS4TWM2OCB;IEG2MlYh|ryP NIe1Tno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C3O|IzQCd-MkewO|czOjh:L3G+
HeLa cells NYPOZoJRS3m2b4TvfIlkcXS7IHHzd4F6 NUXMfGljOyCmYYnz NXvqT2xjUUN3MDC9JFE3NjhizszN M3fOTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEe3NlI5Lz5{N{C3O|IzQDxxYU6=
Raji cells NX;BZVRUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NGL4OVI1QCCq M1jaV2lEPTBiPTCxPU4{KM7:TR?= M33Zc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGyNVc2Lz5{N{mxNlE4PTxxYU6=
Raji cells M3e2UGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MY[0PEBp NWX5NZpLUUN3MDC9JFE6NjNizszN M{nZSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOyPVQ3Lz5{OESzNlk1PjxxYU6=
Raji cells NVW5WJNTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MlrQO|IhcA>? MVLJR|UxKD1iMUmuOUDPxE1? M4K0dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEC2NVQ{Lz5|MECwOlE1OzxxYU6=
Raji cells NEDITXdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MmPCOFghcA>? M2LTVmlEPTBiPTCxPU42KM7:TR?= NU[4RYcyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5OVYxOzdpPkK3PVU3ODN5PD;hQi=>
NAMALWA cells MmLYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NVmxb|VNPzJiaB?= Ml7uTWM2OCB;IEG5MlYh|ryP MmfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xOFMoRjNyMEC2NVQ{RC:jPh?=
A2780 cells MX3DfZRwfG:6aXPpeJkh[XO|YYm= NFXPR5M{KGSjeYO= NVS2R4hTTUN3MDC9JFIxNjFizszN MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB5N{KyPEc,OjdyN{eyNlg9N2F-
Raji cells M3rKSmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MVK3NkBp NX64OlViUUN3MDC9JFIxNjh6IN88US=> NH3Zem89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG0OlE{Pid-MkmxOFYyOzZ:L3G+
A549 cells NH7lfJVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NIXISIM4OiCq Mmr1TWM2OCB;IEKxMlc6KM7:TR?= MmH5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5M{S1PFEoRjJ6N{O0OVgyRC:jPh?=
SW480 cells NUL5XY5YS3m2b4TvfIlkcXS7IHHzd4F6 NIrRe|k{KGSjeYO= M3:w[2lEPTBiPTCyOU43KM7:TR?= NWTaW2d{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewO|czOjhpPkK3NFc4OjJ6PD;hQi=>
Ramos cells M3fSPGN6fG:2b4jpZ4l1gSCjc4PhfS=> MYqyOEBp NUDPSVE2UUN3MDC9JFI5NjdizszN MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ5NE[3OUc,Ojh{N{S2O|U9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pEGFR(Tyr1068) / EGFR; 

PubMed: 28061447     


Ibrutinib inhibitory effects on EGFRY1068 auto-phosphorylation in the HCC827 cell line at different time points by removal of drug after 4 h pretreatment.

pBTK / pPLCγ2 / pAKT / pERK / pJNK; 

PubMed: 23940282     


Mino (left panel) or Jeko1 (right panel) cells pretreated with vehicle or ibrutinib 10, 100, or 1000 nM were either stimulated with anti-IgM, CXCL12, or CXCL13 or treated with medium (Med) for 15 minutes and then immunoblotted for pBTK, pPLCγ2, pAKT, pERK, and pJNK.

28061447 23940282
Immunofluorescence
CD11b; 

PubMed: 30231870     


BV2 microglial cells were pretreated with ibrutinib (1 μM) or vehicle (1% DMSO) for 30 min, followed by treatment with LPS (1 μg/ml) or PBS for 5.5 h and immunostaining with an anti-CD11b antibody. Scale bar = 20 μm.

COX-2; 

PubMed: 30231870     


BV2 microglial cells were treated with vehicle (1% DMSO) or ibrutinib (1 μM) for 30 min, followed by PBS or LPS (1 μg/ml) for 5.5 h, and immunocytochemistry was conducted with anti-CD11b and anti-COX-2 antibodies. 

30231870
ELISA
hTNFα; 

PubMed: 26627823     


PBMs were isolated and pretreated with 1, 5, or 10 μm ibrutinib (IB) or left untreated (UT, −). Pretreated PBMs were incubated for 24 h in 96-well plates precoated without (PBS) or with 10 μg/ml whole human IgG. Cleared supernatants were collected and analyzed by ELISA for TNFα (n = 3).

IL-10; 

PubMed: 27792904     


LMP2A-negative (vector.1/.2) and -positive (express LMP2A) B cell lines were incubated in the absence or presence of increasing concentrations of Ibrutinib for 24 hours and supernatants were isolated for analysis using an IL-10 ELISA.

26627823 27792904
体内研究

Ibrutinib 作用于胶原诱导的关节炎模型,通过抑制B细胞活性,显著降低足肿胀和关节发炎等临床关节炎症状。Ibrutinib 作用于 MRL-Fas(lpr) 狼疮模型 ,降低肾疾病和自身抗体产量。[1] Ibrutinib 每天按25 mg/kg剂量作用于过继转移TCL1 的CLL小鼠模型, 产生短暂的早期淋巴细胞增多症,且延迟CLL 疾病进展。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

激酶实验:

激酶, 33P-ATP, Ibrutinib, 和底物 [0.2 mg/mL 聚(EY)(4:1)]温育1小时后,使用33P 过滤结合实验测量体外激酶IC50值。
细胞实验:

[2]

- 合并
  • Cell lines: 慢性淋巴细胞白血病 (CLL) 细胞
  • Concentrations: 0.01 μM到100 μM
  • Incubation Time: 48小时
  • Method:

    进行MTT实验测定细胞毒性。细胞(CLL B 细胞或健康志愿者T 细胞或 NK细胞) 和不同浓度 Ibrutinib温育48小时。加入MTT试剂,实验板再温育20小时,然后使用溶于PBS的硫酸鱼精蛋白冲洗。加入DMSO,通过分光光度法使用Labsystems 酶标仪,在540 nm处测定吸光值。使用膜联蛋白/PI 流式细胞仪在不同时间点测量细胞活力。使用 Expo-ADC32 软件包分析数据。结果表示为总阳性细胞与对照组之比的百分数。加入100μM Z-VAD检测caspase依赖性凋亡。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: MRL-Fas(lpr) 狼疮模型和胶原诱导的关节炎模型
  • Dosages: ≤50 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 88 mg/mL (199.77 mM)
Ethanol 45 mg/mL (102.15 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+5% Tween 80+ddH2O
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 440.5
化学式

C25H24N6O2

CAS号 936563-96-1
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04294641 Recruiting Drug: Ibrutinib Chronic GVHD National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 5 2021 Phase 2
NCT04665115 Not yet recruiting Drug: Ibrutinib|Other: Quality-of-Life Assessment Asymptomatic COVID-19 Infection Laboratory-Confirmed|B-Cell Neoplasm|Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Symptomatic COVID-19 Infection Laboratory-Confirmed|Waldenstrom Macroglobulinemia Academic and Community Cancer Research United|National Cancer Institute (NCI) December 31 2020 Phase 2
NCT04514393 Not yet recruiting Drug: Methotrexate|Drug: Ibrutinib|Drug: Temozolomide Primary Central Nervous System Lymphoma|PCNSL|Non Hodgkin Lymphoma Huiqiang Huang|Guangdong 999 Brain Hospital|Nanfang Hospital of Southern Medical University|Xian-Janssen Pharmaceutical Ltd.|Sun Yat-sen University December 1 2020 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to reconstitute the compound S2680 for in vivo studies?

  • 回答:

    For in vivo study, we suggest to use 5% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 10mg/ml.

Tags: 购买Ibrutinib (PCI-32765) | Ibrutinib (PCI-32765)供应商 | 采购Ibrutinib (PCI-32765) | Ibrutinib (PCI-32765)价格 | Ibrutinib (PCI-32765)生产 | 订购Ibrutinib (PCI-32765) | Ibrutinib (PCI-32765)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID